| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Dept of General Practice, University of Nijmegen, 2 Dept of General Practice, University of Maastricht, 3 Dept of Pulmonary Diseases, Dekkerswald, University of Nijmegen and 4 Dept of Pulmonary Diseases, Rijnstate Hospital, Arnhem, the Netherlands
CORRESPONDENCE: C.P. van Schayck, Dept of General Practice, University of Maastricht, P.O. Box 616, 6200 MD, Maastricht, The Netherlands. Fax: 31 433884225. E-mail: onno.vanschayck@hag.unimaas.nl
Keywords: asthma, dyspnoea perception, long-acting ß2-agonist, short-acting ß2-agonist
Received: January 18, 2001
Accepted October 20, 2001
Asthma patients evaluate the effect of medication treatment through the degree of their asthma symptoms, which might be affected by their ability to perceive these symptoms. It has been suggested that ß2-agonists may mask the effects of an increase in airway inflammation. This study compared the perception of histamine-induced bronchoconstriction during monotherapy with short- or long-acting ß2-agonists.
Asthmatic patients (68 male and 60 female, mean age 35±11 yrs, forced expiratory volume in one second (FEV1) 86±15% of the reference value, provocative concentration causing a 20% fall in FEV1 (PC20) geometric mean 0.97 mg·mL–1 (95% confidence interval (CI): 0.73–1.30)) were selected and randomly allocated to use either a short-acting (salbutamol, n=41) or long-acting ß2-agonist (formoterol, n=46) or placebo (n=41) for 12 weeks. Perception of dyspnoea provoked by histamine-induced bronchoconstriction was measured at the start and every 4 weeks thereafter. Subjects quantified their sensation of breathlessness during the challenge tests on a modified Borg scale at the start of the study and every 4 weeks thereafter. The sensitivity to changes in FEV1 was analysed by the linear regression slope (
Although the geometric mean PC20 decreased significantly within the group using short-acting ß2-agonists (in the group with initial PC20
This study showed that chronic use of short- or long-acting ß2-agonists in asthmatics for a period of 12 weeks, did not significantly change the perception of histamine-induced bronchoconstriction compared with placebo. Further investigation is required to establish whether this suggests that these drugs do not mask a deterioration of asthma.
) Borg versus % fall in FEV1. The absolute perceptual magnitude (PS20) was determined by the perception score at the 20% fall in FEV1. 
2 mg·mL–1 there was a drop from 5.26–1.94 mg·mL–1; p=0.013), repeated measurement analysis showed no difference in the course of time of perception (both slope and PS20) between the three medication groups.
This article has been cited by other articles:
|
|
 |
|
  S. R. Salpeter, N. S. Buckley, T. M. Ormiston, and E. E. Salpeter Meta-Analysis: Effect of Long-Acting {beta}-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths Ann Intern Med, June 20, 2006; 144(12): 904 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Meta-Analysis: Respiratory Tolerance to Regular {beta}2-Agonist Use in Patients with Asthma Ann Intern Med, May 18, 2004; 140(10): 802 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. McFadden Jr. Acute Severe Asthma Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 740 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Panditi and M Silverman Perception of exercise induced asthma by children and their parents Arch. Dis. Child., September 1, 2003; 88(9): 807 - 811. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
